



Attorney Docket Number XMP 2037  
Serial Number 09/754,347

PATENT

#6  
LP

IN THE UNITED STATE PATENT AND TRADEMARK OFFICE

In re application of: : Gelber, Daniel et al.  
: :  
For: : COMPOSITION AND METHOD FOR  
: : TREATING THE EFFECTS OF  
: : DISEASES AND MALADIES  
: :  
Serial No. : 09/754,347  
: :  
Filed : January 5, 2001  
: :  
Art Unit : 1651  
: :  
Examiner : Jean Witz  
: :  
Attorney Docket No. : XMP 2037

RECEIVED

SEP 16 2002

TECH CENTER 1600/2900

**RESPONSE TO ELECTION OF SPECIES REQUIREMENT**

Assistant Commissioner for Patents  
Washington, DC 20231

Dear Sir:

Responsive to the Examiner,s Office Action dated August 13, 2002 requiring an election of species, the applicants, through their representatives, provisionally elect the combination of an antihistamine pharmaceutical (A) and an anti-inflammatory (I) as a nutraceutical. (This election is without traverse).

The examiner further requires election of a specific anti-inflammatory. The applicant provisionally elects stinging nettle and extracts thereof.

Since some of the claims under consideration include additional ingredients, the examiner further required election of a specific immune boosting nutraceutical and a specific anti-oxidant. The applicant provisionally elects zinc and effective salts thereof as an immune booster and ascorbic acid and effective salts thereof as anti-oxidants.


The combination of an antihistamine pharmaceutical (A) and an anti-inflammatory (I) as a nutraceutical is covered by Claims 1-6, 8, 14, 16, 30, 31, 50- 59, 61, 67, 69, 83, 84, and 104-106. Of these claims, Claims 1-6 and 54-59 are generic.

The following claims cover the combination of an antihistamine, an immune-boosting nutraceutical, and an anti-inflammatory: 14, 16, 67, and 69. The following claims cover the combination of an antihistamine, an anti-oxidant nutraceutical, and an anti-inflammatory: 30, 31, 83, and 84. Because the applicant has already elected a specific immune boosting nutraceutical and a specific anti-oxidant, as required by the examiner, it is requested that Claims 14, 16, 30, 31, 67, 69, 83, and 84 be included in the elected group.

In the alternative, should the examiner not find this argument convincing, the applicant, through his representatives, elects the combination of an antihistamine pharmaceutical (A) and an anti-inflammatory (I) as a nutraceutical, covered by Claims 1-6, 8, 50- 59, 61, and 104-106.

Please note that the examiner included Claims 50-53 and 104-106 as covering A+I. Claims 8 and 61 have been added to this list on the grounds that they cover the combination of a pharmaceutical and a generic nutraceutical. The examiner asserted that Claims 4-5 and 57-58 cover species A+B and A+O, but not species A+I; however, as these claims do not exclude the presence of an anti-inflammatory agent, it is the applicant's contention that they should be treated as generic claims.

Respectfully submitted,



Thomas A. Powers  
Reg. No. 38,582

Dated: September 12, 2002

KRAMER & ASSOCIATES, P.C.  
Crystal Plaza One  
2001 Jefferson Davis Highway, Suite 1101  
Arlington, Virginia 22202  
Telephone: (703) 413-5000  
Facsimile: (703) 413-5048

TWK:AMA:nsa



PTO/SB/21 (12-97)  
Approval for use through 9/30/00. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  <i>(to be used for all correspondence after initial filing)</i>	<b>Applicati n Numb r</b>	09/754,347
	<b>Filing Dat</b>	January 5, 2001
	<b>First Named Inventor</b>	Daniel Gelber
	<b>Group Art Unit</b>	1651
	<b>Examiner Name</b>	Jean Witz
<b>Total Number of Pages in This Submission</b>	3	<b>Attorney Docket Number</b> XMP 2037

RECEIVED  
SEP 16 2002  
TECH CENTER 1600/2900

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communications to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communications to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> To Convert a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Additional Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request of Refund	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

<b>SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT</b>	
Firm or Individual name	Thomas A. Powers, Reg. No. 38,582
Signature	
Date	September 12, 2002

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: <span style="border: 1px solid black; display: inline-block; width: 100px; height: 1.2em; vertical-align: middle;"></span>	
Typed or printed name	
Signature	Date

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.